Filter by

Search tool

Displaying 51 - 55 of 55
Publications
Risk assessments

Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in...
Publications
Risk assessments

Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious...
Publications
Risk assessments

Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing...
Publications
Manuals and guidelines

Guidelines for the risk assessment of new synthetic drugs

This publication was drawn up by the steering group created by the EMCDDA's Scientific Committee in November 1998 to establish guidelines to assess the risks of all new synthetic drugs identified under...
Publications
Risk assessments

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange...
Top